Goals and Objectives:
- Understand the major presenting symptoms of Holt-Oram Syndrome (HOS)
- Describe the genetics and mode of transmission of HOS
- Be able to provide genetic counseling to patients and family with HOS
- Be able to clinically manage patients with HOS
Case Study:
A newborn female is referred to your pediatric cardiology clinic by her primary
physician. The primary pediatrician had noted a murmur on the cardiac exam
and fusion of the second and third carpal bone of the left hand on x-ray.
Family history is significant for a maternal uncle who had similar features.
An electrocardiogram and an echocardiogram are ordered; these tests reveal
that the patient does indeed have a murmur—an ASD. What should you,
as the cardiologist do next? How should you guide the family?
Pretest Questions:
- What is the epidemiology of HOS?
- What are the clinical features of HOS?
- What type of murmur would you expect to hear?
- What is the differential diagnosis of HOS?
- What is the mode of transmission and the genes involved in HOS?
- What is the pathophysiology of HOS?
- Is genetic testing needed for a patient found to have HOS? What more needs
to be done?
- What is the clinical management of these patients?
Answers:
- What is the epidemiology of HOS?
HOS is estimated to occur in about 1/100,000 live births. It has been reported
from a number of countries worldwide, in individuals of varying racial and
ethnic backgrounds. Both sexes are affected equally, although the defects tend
to be more severe in females. The syndrome itself has no mortality. The morbidity
and mortality relates directly to the associated congenital abnormalities,
particularly cardiac. For example, mortality and morbidity of a secundum atrial
septal defect (ASD) is negligible throughout childhood including those patients
undergoing a procedure to close the ASD. Causes of death most often include
cardiac malformation and heart block.
- What are the clinical features of HOS?
HOS is also known as the heart-hand syndrome. The natural history of HOS varies
and is largely dependent on the severity of the congenital heart malformation.
Individuals with more severe congenital heart defects may even present in the
neonatal period often detected in utero by fetal ultrasound echocardiography. Malformations
are first detected at birth. Upper-limb malformation most often involves
the radial, thenar, or carpal bones. These malformations
are variably expressed, and may be unilateral or bilateral. Upper-limb malformations
can include: absent thumb(s), phocomelia (the hands are attached close to the
body), unequal arm length (from aplasia), hypoplasia of the radius, fusion
or anomalous development of the carpal and thenar bones, abnormal forearm pronation
and supination, abnormal opposition of the thumb, and sloping shoulders and
restriction of shoulder joint movement. Abnormalities are often more severe
in the left upper limb than in the right upper limb. All affected individuals
have, at a minimum, an abnormal carpal bone, which can be the only evidence
of disease, identified by performing a PA hand X-ray.
In addition to upper-limb malformations, individuals with HOS can also have
congenital heart malformations. Seventy-five percent of individuals with HOS
have a congenital heart defect. The defect most commonly seen is ostium secundum
ASD and muscular septal VSD. Whether or not individuals have a heart defect,
patients with HOS are at risk for cardiac conduction disease. Patients may
present at birth with sinus bradycardia and first-degree atrioventricular (AV)
block, which can progress to complete heart block with and without atrial fibrillation.
Cardiac arrhythmias also seen include paroxysmal tachycardia, prolonged PR
interval, wandering atrial pacemaker, and atrial ectopies. Complications, which
can be life threatening if not recognized and appropriately managed, include:
congestive heart failure, pulmonary hypertension, arrhythmias, heart block,
atrial fibrillation, and infective endocarditis. Some individuals with severe
congenital heart malformation may require surgery early in life to repair significant
septal defects.
Because HOS is a clinical diagnosis, HOS can be excluded in individuals with
congenital malformations involving the following structures or organ systems:
kidney, vertebra, craniofacies, auditory system (hearing loss or ear malformations),
lower limb, anus, or eye.
A scoring system to assess severity on an individual with HOS has been recommended
by Gall et al and modified by Gladstone and Sybert.
Table 1. Scoring System to Assess Skeletal Abnormalities in Holt-Oram Syndrome
0 |
No abnormality on physical or radiological
examination |
1 |
Minor abnormalities, including reduced
thenar eminence, clinodactyly or hypoplasia of the thumb |
2 |
Triphalangeal or aplastic thumbs, radial/ulnar
hypoplasia |
3 |
Arms and forearms present but with bone(s)
missing |
4 |
Phocomelia |
Table 2. Scoring System to Assess Cardiac Abnormalities in Holt-Oram Syndrome
0 |
Asymptomatic, with no abnormal physical
findings |
1 |
Conduction defect |
2 |
Structural heart abnormality not requiring
surgery |
3 |
Structural heart abnormality requiring
surgery, but not life threatening |
4 |
Potentially lethal malformation |
- What type of murmur would you expect to hear?
S1 is split, and the S2 component may be increased in intensity, reflecting
forceful right ventricular contraction and delayed closure of the tricuspid
leaflets. ASDs with moderate-to-large left-to-right shunts produce a pulmonary
outflow murmur that begins shortly after the S1, peaks in early-to-mid systole
and ends before the S2. S2 is also widely split and fixed because of the delayed
pulmonic valve closure (in almost all patients with large left-to-right shunts).
Increased right ventricular stroke volume across the pulmonary outflow tract
creates a crescendo-decrescendo midsystolic (ejection) murmur in the second
interspace at the left sternal border. Patients with large left-to-right shunts
may also have a rumbling middiastolic murmur at the lower left sternal border
because of increased flow across the tricuspid valve.
- What is the differential diagnosis of HOS?
The differential can be broken down into the following:
èAutosomal dominant disorders
Okihiro syndrome (Duane-radial
ray syndrome)
Ulnar-mammary syndrome
(UMS)
Townes-Brocks syndrome
(TBS)
Heart-hand syndrome II (Tabatznik)
Heart-hand syndrome III
Long thumb branchydactyly
syndrome
èAutosomal recessive disorders
Fanconi anemia (FA) syndrome
Thrombocytopenia-absent
radius syndrome (TAR)
èChromosomal etiology
22q11.2 deletion syndrome (del
22q11.2)
èDisorders of unknown cause
VACTERL
èTeratogen exposure (thalidomide, valproate)
- What is the mode of transmission and the genes involved in HOS?
HOS is transmitted in an autosomal dominant manner. The gene involved
in this syndrome is TBX5 on chromosome 12q24.1.
- What is the pathophysiology of HOS?
TBX5 functions as a transcription factor in the T-box gene family, that
has an important role in both cardiogenesis and limb development. Over 30 mutations
have been described, ranging from missense, nonsense mutations to large deletions.
It is hypothesized that most nonsense and frameshift mutations lead to
mutant TBX5 mRNAs that are degraded with resulting haploinsufficiency or that
some missense mutations result in transcripts that have diminished DNA
binding activity. Both result in a reduced TBX5 gene dose, which leads to HOS.
Consequent abnormal expression of the cardiac and limb-specific T-box transcription
factors lead to the malformations described in HOS.
- Is genetic testing needed for a patient found to have HOS? What
more needs to be done?
Genetic testing can be useful in identification of at-risk family members
for appropriate cardiac management, and genetic counseling which may be
useful for predicting recurrence risks for future offspring of affected
individuals. Some
individuals diagnosed with HOS have an affected parent. In a patient found
to have HOS, even if it appears to be de novo, evaluation of the parents
should be undertaken to prevent complications in both the parents, and for
future progeny. Evaluation should include echocardiography, ECG, and hand x-rays
to determine their affected status. Additionally, molecular genetic testing
can be performed on the parents if the TBX5 mutation in the child has been
identified.
Siblings of patients affected with HOS depends upon the genetic status of
the parents. If a parent is affected, the risk to the siblings is 50%. If the
parents are clinically unaffected and do not have a disease-causing mutation,
the risk to the siblings is low (similar to the general population risk).
Offspring of affected patients are at 50% risk of being affected. Because of
the effects of modifying genes and the significant variable expressivity
observed in individuals with HOS, the phenotype of affected offspring cannot
be accurately predicted. The risk to other family members depends upon the
status of the patient’s parents. If a parent is found to be affected,
his or her family members are at risk.
The optimal time for determination of genetic
risk and discussion of the availability of prenatal testing is before pregnancy. DNA banking can be utilized for future
use to study genes of affected family members. Because it is likely that testing methodology and our
understanding of genes, mutations, and diseases will improve in the future, consideration should be
given to banking DNA. In pregnancies at 50% risk, detailed high-resolution prenatal ultrasound examination
may detect upper-limb malformations and/or congenital heart malformations. However, a normal ultrasound
examination does not eliminate the possibility of HOS in the fetus. Prenatal testing for HOS may be
most useful in families with a known mutation to confirm ultrasound findings.
Prenatal diagnosis
for pregnancies at increased risk is possible by analysis of DNA extracted by amniocentesis performed
at about 15-18 weeks' gestation. Because of the significant variable expressivity observed in
individuals with HOS, both within and among families with the same mutation, the severity of upper-limb
defects and congenital heart malformations cannot be accurately predicted by molecular genetic testing
alone.
- What is the clinical management of these patients?
The management of individuals with HOS should involve a multidisciplinary
team approach, including specialists in medical genetics, cardiology, and orthopedics,
including a specialist in hand surgery. A cardiologist can assist in determining
the need for antiarrhythmic medications and surgery. Individuals with severe
heart block may require pacemaker implantation. Pharmacologic treatment for
affected individuals with pulmonary hypertension may be appropriate. Individuals
with pulmonary hypertension and/or structural heart malformation may require
tertiary care center cardiology follow-up. The orthopedic team may help decide
options for surgery for improved upper limb and hand function, as well as physical
and occupational therapy options. Those individuals born with severe upper-limb
malformations may be candidates for surgery such as pollicization (creation
of a thumb-like digit by moving another digit into the thenar position). Children
with severe limb shortening may benefit from prostheses.
For preventative measures anticoagulants and antibiotic prophylaxis for bacterial
endocarditis (SBE) can be administered in patients with congenital heart malformations.
Resources for patients:
National Library of Medicine Genetics Home Reference
Holt-Oram
syndrome
American Heart Association
National Center
7272 Greenville Avenue
Dallas TX 75231
Phone: 800-AHA-USA-1 (800-242-8721)
www.americanheart.org
Congenital Heart Information Network (CHIN)
1561 Clark Drive
Yardley PA 19067
Phone: 215-493-3068
Email: mb@tchin.org
http://www.tchin.org/
Reach: The Association for children with Hand or Arm Deficiency
PO Box 54
Helston
Cornwall TR13 8WD
United Kingdom
Phone: (+44) 0845 1306 225
Fax: (+44) 0845 1300 262
Email: reach@reach.org.uk
www.reach.org.uk
Citations:
OMIM
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142900
GeneReviews
www.genetests.com
Hunt, SA, Abraham, WT, Chin, MH, et al. ACC/AHA 2005 Guideline Update for
the Diagnosis and Management of Chronic Heart Failure in the Adult: a report
of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for
the Evaluation and Management of Heart Failure): developed in collaboration
with the American College of Chest Physicians and the International Society
for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation
2005; 112:e154.
Gall J.C, Stern A.M, Cohen M.M, Adams M.S, Davidson R.T. Holt-Oram syndrome:
clinical and genetic study of a large family. Am. J. Hum.
Genet. 18: 187-200, 1966.
Gladstone I, Sybert V.P. Holt-Oram syndrome:
penetrance of the gene and lack of maternal effect. Clin.
Genet. 21: 98-103, 1982.
Venugopalan P (2006). Holt-Oram Syndrome. Retrieved August 23, 2006 from http://www.emedicine.com/ped/topic1021.htm#section~author_information.
|